MedTrace Logo

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

NCT01974284 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-11-25

Study results available
· View outcomes & findings →

Summary

We assess the effectiveness of percutaneous ethanol ablation for the treatment of thyroid cancer.

Conditions

  • Papillary Thyroid Cancer

Interventions

DRUG

percutaneous ethanol ablation

The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Glenda Callender, MD · Yale University- Department of Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2017-03-02
Completion
2017-06-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974284 on ClinicalTrials.gov